MetaVia reported Phase 1 interim data for DA-1726, a once-weekly dual oxyntomodulin analogue engaging GLP-1 and glucagon receptors at a 3:1 potency ratio, showing a 13.5% placebo-adjusted body weight reduction and a 68% placebo-adjusted reduction in liver fat at Day 109. Visceral and subcutaneous fat both declined while lean mass was relatively preserved. The compound is positioned for Phase 2 evaluation in alcohol-related and metabolic dysfunction-associated liver disease beginning in 2027.
Key Points
- 13.5% placebo-adjusted weight loss at Day 109, Phase 1
- 68% placebo-adjusted liver fat reduction with preserved lean mass
- Glucagon receptor engagement adds energy expenditure to appetite suppression
Longevity Analysis
Adding glucagon receptor activity to GLP-1 agonism shifts the mechanism from appetite suppression alone toward increased energy expenditure and direct hepatic fat mobilization, which matters because visceral and liver fat drive the inflammatory and metabolic burden most closely tied to accelerated aging. Preservation of lean mass is the critical variable in this class, since muscle loss undermines the long-term metabolic and functional gains that weight reduction is meant to deliver. Pharmacological fat clearance works best when the underlying drivers of hepatic fat accumulation are also removed, and durability will depend on whether these changes persist once treatment is sustained over years rather than months.
Original published by LT Wire.